New York, NY, and Tel Aviv, ISRAEL, Sept. 30, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. TOMDF, a comprehensive medical diagnostics and related solutions company, today announced that it has received two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent applications covering the Company’s Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform. The Notices of Allowance are for patent applications entitled 1) “Infrared (IR) Spectroscopy System” and 2) “Infrared Analysis of Benign Tumors.” The Company has already received CE marks for its TBIA blood diagnostic test in breast cancer and colon cancer.
The key allowed claim for Infrared (IR) Spectroscopy System patent application was surrounding the system of collecting blood, obtaining FTIR spectrum from peripheral blood lymphocytes, and an output unit, configured to generate an output indicative of the presence of a solid tumor. The claim allowed for the patent application Analysis of Benign Tumors was related to the necessary conditions to capture consistent data to yield actionable results.
“The allowance of these two seminal pieces of intellectual property underlying the Company’s TBIA FTIR pan-cancer diagnosis platform, which we believe will ultimately outcompete the liquid biopsy platform for routine testing of asymptomatic and early-stage cancer patients, including tests such as Illumina’s Galleri®,” said Gerald Commissiong, President & CEO of Todos Medical. “As we prepare to launch our Videssa breast cancer test in 2023, it will be very important to capture TBIA FTIR data from each patient tested with Videssa so we can continue to build the TBIA FTIR algorithm in order to gather sufficient data to submit to FDA. This platform will allow us to test for multiple cancers from the same blood sample because of the power of spectroscopy, as compared with more traditional antibody-based assays that make multiplexing challenging. We are very excited to be able to allow this technology to mature appropriately while we launch Videssa in the market.”
The global cancer diagnostics market size is expected to be increase to approximately USD $258 billion by 2030 from USD $124 billion in 2021, according to Precedence Research. The global cancer diagnostics market is expected to experience growth at a CAGR of 8.4% over the forecast period 2022 to 2030.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. TOMDF engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL protease–based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid™ in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, while also developing the 3CL protease diagnostic TolloTest™.
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch CFO
917-983-4229 x 104
Todos Press Contact:
Read the original article